

**HOLD**

TP: Rs 190 | ▲ 9%

**FINOLEX INDUSTRIES**

| Building Materials

| 02 February 2026

## Margins hold up on mix improvement and spread lag

- FNXP trails peers on muted demand for agri pipes; rev declined ~10% YoY led by vol decline of ~14% YoY while realisations grew 5% YoY
- EBITDA margins (5.7pp above our estimates) a positive surprise. Margins expanded 8.4pp YoY, on an improving mix
- Cut FY27-28 estimates, roll forward to Dec'26 TP of Rs 190 (ascribing unchanged multiple of 22x) and limited upside. Downgrade to HOLD

**Vineet Shanker**  
 Research Analyst  
 research@bobcaps.in

**Mixed Q3:** FNXP's Q3FY26 topline was a miss, with revenues declining 10% YoY and volumes falling 14% YoY — materially below our expectations, reflecting the continued weakness in agri demand in Q3FY26. However, gross margin improved by 8.4pps to 42.6%, which led to significant growth in EBITDA (+ 48% YoY, beating our estimate by ~34%), on account of a favourable product mix (higher mix of non-agri pipes) and structural cost advantages (70-75% of resin consumption is backwardly integrated). APAT went up 24.7% YoY to Rs 1.16bn.

**Underperformance vs peers indicate continued market share loss:** FNXP continued to underperform peers on volume growth in Q3FY26 (SI: +16.2%; APOLP: -5.9%; FNXP: -14.3%), indicating the ongoing market share loss, largely led by agri pipes. However, profitability improved meaningfully, with blended EBITDA per unit rising to Rs 16.7/kg in Q3FY26 (vs Rs 9.7/kg in Q3FY25), supported by higher non-agri contribution (38% of volumes), improved pricing discipline and benefits of backward integration. Net cash position improved sequentially to Rs 24.3bn, as of Dec'25, while channel inventory remained below normal levels, with the early signs of restocking visible in Jan'26.

**PVC resin prices bottoming out:** Management believes that PVC prices have bottomed out and guided for a flattish-to-marginal volume growth in FY26, while maintaining EBITDA margins in the 10-12% range. Capex is estimated to be Rs 1-1.5bn in FY26.

**Revise estimates, downgrade to HOLD:** We downgrade the stock to HOLD on a limited upside and restricted re-rating potential. We align our Q4 volume assumptions with management's flattish growth guidance, while upgrading FY26E EBITDA on an improving gross margin profile that is driven by product mix. We trim FY27-28E assumptions to reflect a continued market share loss in the core business. Rolling forward to Dec'27E EPS and valuing at an unchanged 22x, we arrive at a TP of Rs 190.

## Key changes

	Target	Rating
Ticker/Price	FNXP IN/Rs 175	
Market cap	US\$ 1.2bn	
Free float	48%	
3M ADV	US\$ 1.1mn	
52wk high/low	Rs 238/Rs 154	
Promoter/FPI/DII	52%/6%/12%	


Source: NSE | Price as of 2 Feb 2026

## Key financials

Y/E 31 Mar	FY25A	FY26E	FY27E
Total revenue (Rs mn)	41,420	40,688	47,533
EBITDA (Rs mn)	4,758	5,104	5,687
Adj. net profit (Rs mn)	4,802	5,033	5,116
Adj. EPS (Rs)	7.8	8.1	8.3
Consensus EPS (Rs)	7.8	8.1	9.8
Adj. ROAE (%)	8.2	8.1	7.9
Adj. P/E (x)	22.5	21.5	21.1
EV/EBITDA (x)	18.6	17.0	15.1
Adj. EPS growth (%)	1.0	4.8	1.7

Source: Company, Bloomberg, BOBCAPS Research

## Stock performance



Source: NSE



**Fig 1 – Quarterly performance - Consolidated**

Particulars	Q3FY26	Q3FY25	YoY (%)	Q2FY26	QoQ (%)	9MFY26	9MFY25	YoY (%)	BOBCAPS Q3FY26E	Q3FY26
Revenue	8,977	10,012	(10.3)	8,587	4.5	27,996	29,702	(5.7)	11,459	8,977
RM	5,149	6,585	(21.8)	4,922	4.6	17,100	19,082	(10.4)		5,149
Gross Profit	3,827	3,428	11.7	3,665	4.4	10,896	10,620	2.6		3,827
Employee	703	570	23.3	520	35.1	1,806	1,710	5.6		703
Others	1,894	2,023	(6.4)	1,843	2.7	5,621	5,903	(4.8)		1,894
EBITDA	1,231	834	47.5	1,302	(5.4)	3,468	3,007	15.4	918	1,231
D&A	265	273	(3.0)	274	(3.5)	805	798	0.9		265
EBIT	966	561	72.1	1,027	(6.0)	2,663	2,208	20.6		966
Interest cost	30	100	(69.8)	43	(29.8)	128	235	(45.3)		30
Int. & other income	634	657	(3.5)	677	(6.3)	2,006	2,057	(2.5)		634
PBT	1,570	1,118	40.4	1,661	(5.5)	4,540	4,031	12.6		1,570
Tax	409	178	130.0	425	(3.9)	1,162	1,846	(37.0)		409
PAT	1,161	940	23.5	1,236	(6.1)	3,378	2,184	54.6		1,161
Adj. PAT	1,161	931	24.7	1,236	(6.1)	3,327	3,009	10.6	941	1,161
As % of net revenues			chg (bps)		chg (bps)			chg (bps)		
Gross margin	42.6	34.2	840	42.7	(4)	38.9	35.8	316		
Employee	7.8	5.7	214	6.1	177	6.5	5.8	69		
Others	21.1	20.2	89	21.5	(37)	20.1	19.9	20		
EBITDA margin	13.7	8.3	538	15.2	(145)	12.4	10.1	227		
Tax rate	26.0	15.9	1,015	25.6	44	25.6	45.8	(2,021)		
APAT margin	12.9	9.3	363	14.4	(146)	11.9	10.1	175		

Source: Company, BOBCAPS Research

**Fig 2 – Key operating metrics**


Particulars	Q3FY26	Q3FY25	YoY (%)	Q2FY26	QoQ (%)	9MFY26	9MFY25	YoY (%)
Pipe sales volume (kt)	74	86	(14.3)	65	12.5	231	246	(6.0)
Pipe sales realisation (Rs/kg)	122	116	5.5	131	(7.1)	121	121	0.3
Blended EBITDA per unit (Rs/kg)	16.7	9.7	72.1	19.9	(15.9)	15.0	12.2	22.7

Source: Company, BOBCAPS Research

## Earnings Call Highlights


- **Demand Scenario:** Q3FY26 saw muted demand due to extended monsoons. Management noted that Q4 historically witnesses a seasonal pickup across the industry and expects the trend to continue. Jan'26 showed a good traction with improving sentiment post the price increases.
- **PVC resin price outlook:** PVC prices have hit low levels of ~USD 600-620/MT in Q3FY26 amid a volatile geopolitical scenario, but improved 8-9% by Dec'25-end to USD 650-660/MT with a positive outlook for Q4 stabilization or slight uptick. Management believes PVC has bottomed, citing global capacity rationalisation (western plant shutdowns, similar trends emerging in China) and China's recent changes to export incentive structures. Outlook is cautiously positive for price stabilisation.
- **Guidance:** For FY26, management guided for flattish-to-marginal volume growth YoY, with Q4 expected to be stronger sequentially. On margins, management aims to broadly maintain current EBITDA margin levels at 10-12% over near-to-medium term.
- **Pipe:** Sales volume declined by 14.3% YoY in Q3FY26, with weakness largely attributable to agri demand and weather-related disruptions. CPVC share accounted for 8% of the total sales volume in Q3FY26. Non-agri products accounted for a higher share vs that in previous quarter, supporting better realisations. Agri vs non-agri mix stood at 62:38 in Q3FY26, with management reiterating its strategic intent to gradually increase non-agri contribution over time.
- **Fittings:** Stood at 12% of the total sales volume in Q3FY26.
- **Margins:** EBITDA margin expanded by 538 bps to 13.7% in Q3FY26, driven by a combination of improved net realisations (+5.5%YoY in Q3FY26) and structural cost advantages from backward integration. Management explained that despite a decline in PVC-EDC spreads, the lag in raw material pricing, in-house resin sourcing (65-80% of requirement), and pricing discipline — enabled margin expansion.
- **Capex:** FY26 capex planned at Rs 1-1.5bn, consistent with historical Rs 1-2bn annual run-rate. FNXP recently added 50ktpa and discussions are underway for further 50-80ktpa addition by FY27; contingent on demand visibility.
- **Net cash:** balance has risen from Rs23.6bn in Sep'25 to Rs24.3bn in Sep'25. Management indicated that Board discussions are ongoing for utilisation, potentially for dividends/buybacks.
- **Channel Inventory:** Channel inventory remained below normal through most of Q3FY26. However, management observed gradual inventory rebuilding in Jan'26, following PVC price increases and improved sentiment, though inventory levels are still not back to optimal levels.

**Fig 3 – FNXP pipe volume de-grew by 14.3% YoY in Q3FY26, due to extended monsoon**




Source: Company, BOBCAPS Research

**Fig 5 – FNXP pipe volume is projected to grow at 6.4% CAGR over FY25-FY28E**




Source: Company, BOBCAPS Research

**Fig 7 – EPS to grow at a healthy 7.2% CAGR over FY25-FY28E over a weak base**




Source: Company, BOBCAPS Research

**Fig 4 – FNXP blended EBITDA per unit improved sharply in Q3FY26, due to high share of plumbing pipe revenue**




Source: Company, BOBCAPS Research

**Fig 6 – FNXP Pipe EBITDA per unit to structurally improve on higher non-agri pipe sales**



Source: Company, BOBCAPS Research

**Fig 8 – FNXP return ratio profile to remain weak over FY26E-FY28E, on poor capital allocation**



Source: Company, BOBCAPS Research

## Valuation Methodology


We downgrade the stock to HOLD on limited upside and restricted re-rating potential. We align our Q4 volume assumptions with management's flattish growth guidance, while upgrading FY26E EBITDA on an improving gross margin profile, driven by product mix. We trim FY27–28E assumptions to reflect continued market share loss in the core business. Rolling forward to Dec-27E EPS and valuing at an unchanged 22x, we arrive at a TP of Rs 190.

**Fig 9 – Revised estimates**

Consolidated (Rs bn)	New			Old			Change (%)		
	FY26E	FY27E	FY28E	FY26E	FY27E	FY28E	FY26E	FY27E	FY28E
Revenue	40.7	47.5	53.6	44.5	51.4	57.0	(8.6)	(7.5)	(6.0)
EBITDA	5.1	5.7	6.7	4.8	6.3	7.8	5.4	(9.6)	(14.1)
EBITDA margin	12.5	12.0	12.5	10.9	12.3	13.7	167	(29)	(118)
Adjusted PAT	5.0	5.1	5.9	4.8	5.5	6.7	3.8	(7.0)	(11.7)
Adjusted EPS	8.1	8.3	9.6	7.8	8.9	10.8	3.8	(7.0)	(11.7)

Source: BOBCAPS Research

**Fig 10 – Trading at 21.2x 1YF P/E vs 5Y average of 25.0x**



**Fig 11 – Key assumptions**

Particulars (%)	FY24A	FY25A	FY26E	FY27E	FY28E
Pipes volume growth	11.1	3.4	(4.2)	13.8	10.6
Pipe realisation growth	(8.4)	(5.2)	3.5	2.7	2.0
Blended EBITDA per unit (Rs/kg)	17.5	13.7	15.3	15.0	16.0

Source: Company, BOBCAPS Research

## Financials

### Income Statement

Y/E 31 Mar (Rs mn)	FY24A	FY25A	FY26E	FY27E	FY28E
<b>Total revenue</b>	<b>43,174</b>	<b>41,420</b>	<b>40,688</b>	<b>47,533</b>	<b>53,600</b>
EBITDA	5,882	4,758	5,104	5,687	6,706
Depreciation	1,160	1,067	1,050	1,124	1,198
EBIT	4,721	3,691	4,055	4,563	5,508
Net interest inc./exp.)	(365)	(296)	(159)	(121)	(121)
Other inc./exp.)	1,800	2,466	2,395	2,195	2,316
Exceptional items	33	0	0	0	0
EBT	6,123	5,861	6,291	6,637	7,703
Income taxes	1,770	2,432	1,719	1,721	1,989
Extraordinary items	0	(4,170)	0	0	0
Min. int./Inc. from assoc.	382	402	461	200	200
<b>Reported net profit</b>	<b>4,736</b>	<b>8,000</b>	<b>5,033</b>	<b>5,116</b>	<b>5,914</b>
Adjustments	21	(3,198)	0	0	0
<b>Adjusted net profit</b>	<b>4,757</b>	<b>4,802</b>	<b>5,033</b>	<b>5,116</b>	<b>5,914</b>

### Balance Sheet

Y/E 31 Mar (Rs mn)	FY24A	FY25A	FY26E	FY27E	FY28E
Accounts payables	2,886	4,442	4,363	5,097	5,748
Other current liabilities	4,285	3,026	3,026	3,026	3,026
Provisions	45	99	97	113	128
Debt funds	3,820	2,211	2,211	2,211	2,211
Other liabilities	3,201	3,074	3,074	3,074	3,074
Equity capital	1,237	1,237	1,237	1,237	1,237
Reserves & surplus	55,106	59,732	62,291	64,625	67,757
Shareholders' fund	56,343	60,969	63,528	65,862	68,993
<b>Total liab. and equities</b>	<b>70,579</b>	<b>73,819</b>	<b>76,298</b>	<b>79,382</b>	<b>83,179</b>
Cash and cash eq.	22,465	22,694	24,837	24,653	25,699
Accounts receivables	4,576	3,793	3,726	4,352	4,908
Inventories	7,280	7,824	7,285	8,977	10,304
Other current assets	798	448	440	514	579
Investments	23,711	27,656	27,656	27,656	27,656
Net fixed assets	10,411	9,871	10,821	11,697	12,499
CWIP	189	732	732	732	732
Intangible assets	143	213	213	213	213
Deferred tax assets, net	215	51	51	51	51
Other assets	791	539	539	539	539
<b>Total assets</b>	<b>70,579</b>	<b>73,819</b>	<b>76,298</b>	<b>79,382</b>	<b>83,179</b>

### Cash Flows

Y/E 31 Mar (Rs mn)	FY24A	FY25A	FY26E	FY27E	FY28E
<b>Cash flow from operations</b>	<b>4,385</b>	<b>3,958</b>	<b>4,380</b>	<b>2,524</b>	<b>3,634</b>
Capital expenditures	(817)	(1,140)	(2,000)	(2,000)	(2,000)
Change in investments	(4,454)	(3,945)	0	0	0
Other investing cash flows	1,767	6,636	2,395	2,195	2,316
<b>Cash flow from investing</b>	<b>(3,505)</b>	<b>1,551</b>	<b>395</b>	<b>195</b>	<b>316</b>
Equities issued/Others	0	0	0	0	0
Debt raised/repaid	(1,445)	(1,609)	0	0	0
Interest expenses	(1,546)	(2,226)	(2,473)	(2,783)	(2,783)
Dividends paid	(365)	(296)	(159)	(121)	(121)
Other financing cash flows	4,122	(1,148)	0	0	0
<b>Cash flow from financing</b>	<b>767</b>	<b>(5,279)</b>	<b>(2,632)</b>	<b>(2,903)</b>	<b>(2,903)</b>
Chg in cash & cash eq.	1,647	229	2,143	(185)	1,046
<b>Closing cash &amp; cash eq.</b>	<b>22,465</b>	<b>22,694</b>	<b>24,837</b>	<b>24,653</b>	<b>25,699</b>

### Per Share

Y/E 31 Mar (Rs)	FY24A	FY25A	FY26E	FY27E	FY28E
Reported EPS	7.7	12.9	8.1	8.3	9.6
Adjusted EPS	7.7	7.8	8.1	8.3	9.6
Dividend per share	2.5	3.6	4.0	4.5	4.5
Book value per share	91.1	98.6	102.7	106.5	111.6

### Valuations Ratios

Y/E 31 Mar (x)	FY24A	FY25A	FY26E	FY27E	FY28E
EV/Sales	2.1	2.1	2.1	1.8	1.6
EV/EBITDA	15.5	18.6	17.0	15.1	12.7
Adjusted P/E	22.7	22.5	21.5	21.1	18.3
P/BV	1.9	1.8	1.7	1.6	1.6

### DuPont Analysis

Y/E 31 Mar (%)	FY24A	FY25A	FY26E	FY27E	FY28E
Tax burden (Net profit/PBT)	77.7	81.9	80.0	77.1	76.8
Interest burden (PBT/EBIT)	129.7	158.8	155.2	145.5	139.8
EBIT margin (EBIT/Revenue)	10.9	8.9	10.0	9.6	10.3
Asset turnover (Rev./Avg TA)	61.2	56.1	53.3	59.9	64.4
Leverage (Avg TA/Avg Equity)	1.3	1.3	1.2	1.2	1.2
Adjusted ROAE	9.0	8.2	8.1	7.9	8.8

### Ratio Analysis

Y/E 31 Mar	FY24A	FY25A	FY26E	FY27E	FY28E
YoY growth (%)					
Revenue	(1.8)	(4.1)	(1.8)	16.8	12.8
EBITDA	80.9	(19.1)	7.3	11.4	17.9
Adjusted EPS	83.0	1.0	4.8	1.7	15.6
Profitability & Return ratios (%)					
EBITDA margin	13.6	11.5	12.5	12.0	12.5
EBIT margin	10.9	8.9	10.0	9.6	10.3
Adjusted profit margin	11.0	11.6	12.4	10.8	11.0
Adjusted ROAE	9.0	8.2	8.1	7.9	8.8
ROCE	10.8	9.7	9.8	9.9	11.0
Working capital days (days)					
Receivables	39	33	33	33	33
Inventory	62	69	65	69	70
Payables	24	39	39	39	39
Ratios (x)					
Gross asset turnover	1.6	1.5	1.4	1.6	1.7
Current ratio	3.2	3.6	3.7	3.7	3.7
Net interest coverage ratio	13.0	12.5	25.6	37.8	45.6
Adjusted debt/equity	(0.3)	(0.3)	(0.4)	(0.3)	(0.3)

Source: Company, BOBCAPS Research | Note: TA = Total Assets

NOT FOR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA ("US") OR IN OR INTO ANY OTHER JURISDICTION IF SUCH AN ACTION IS PROHIBITED BY APPLICABLE LAW.

## Disclaimer

Name of the Research Entity: **BOB Capital Markets Limited**

Registered office Address: 1704, B Wing, Parinee Crescenzo, G Block, BKC, Bandra East, Mumbai 400051

SEBI Research Analyst Registration No: INH000000040 valid till 03 February 2025

Brand Name: **BOBCAPS**

Trade Name: [www.barodaetrade.com](http://www.barodaetrade.com)

CIN: U65999MH1996GOI098009

Logo:  TRUST | INNOVATION | EXCELLENCE

Investments in securities market are subject to market risks. Read all the related documents carefully before investing.

Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

### Recommendation scale: Recommendations and Absolute returns (%) over 12 months

**BUY** – Expected return >+15%


**HOLD** – Expected return from -6% to +15%

**SELL** – Expected return <-6%

**Note:** Recommendation structure changed with effect from 21 June 2021

Our recommendation scale does not factor in short-term stock price volatility related to market fluctuations. Thus, our recommendations may not always be strictly in line with the recommendation scale as shown above.

### Ratings and Target Price (3-year history): FINOLEX INDUSTRIES (FNXP IN)



B – Buy, H – Hold, S – Sell, A – Add, R – Reduce

### Analyst certification

The research analyst(s) authoring this report hereby certifies that (1) all of the views expressed in this research report accurately reflect his/her personal views about the subject company or companies and its or their securities, and (2) no part of his/her compensation was, is, or will be, directly or indirectly, related to the specific recommendation(s) or view(s) in this report. Analysts are not registered as research analysts by FINRA and are not associated persons of BOB Capital Markets Limited (BOBCAPS).

### General disclaimers

BOBCAPS is engaged in the business of Stock Broking and Investment Banking. BOBCAPS is a member of the National Stock Exchange of India Limited and BSE Limited and is also a SEBI-registered Category I Merchant Banker. BOBCAPS is a wholly owned subsidiary of Bank of Baroda which has its various subsidiaries engaged in the businesses of stock broking, lending, asset management, life insurance, health insurance and wealth management, among others.

BOBCAPS's activities have neither been suspended nor has it defaulted with any stock exchange authority with whom it has been registered in the last five years. BOBCAPS has not been debarred from doing business by any stock exchange or SEBI or any other authority. No disciplinary action has been taken by any regulatory authority against BOBCAPS affecting its equity research analysis activities.

BOBCAPS is also a SEBI-registered intermediary for the broking business having SEBI Single Registration Certificate No.: INZ000159332 dated 20 November 2017.

BOBCAPS prohibits its analysts, persons reporting to analysts, and members of their households from maintaining a financial interest in the securities or derivatives of any companies that the analysts cover. Additionally, BOBCAPS prohibits its analysts and persons reporting to analysts from serving as an officer, director, or advisory board member of any companies that the analysts cover.

Our salespeople, traders, and other professionals may provide oral or written market commentary or trading strategies to our clients that reflect opinions contrary to the opinions expressed herein, and our proprietary trading and investing businesses may make investment decisions that are inconsistent with the recommendations expressed herein. In reviewing these materials, you should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest. Additionally, other important information regarding our relationships with the company or companies that are the subject of this material is provided herein.

This material should not be construed as an offer to sell or the solicitation of an offer to buy any security in any jurisdiction. We are not soliciting any action based on this material. It is for the general information of BOBCAPS's clients. It does not constitute a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual clients. Before acting on any advice or recommendation in this material, clients should consider whether it is suitable for their particular circumstances and, if necessary, seek professional advice. BOBCAPS research reports follow rules laid down by Securities and Exchange Board of India and individuals employed as research analysts are separate from other employees who are performing sales trading, dealing, corporate finance advisory or any other activity that may affect the independence of its research reports.

The price and value of the investments referred to in this material and the income from them may go down as well as up, and investors may realize losses on any investments. Past performance is not a guide for future performance, future returns are not guaranteed and a loss of original capital may occur. BOBCAPS does not provide tax advice to its clients, and all investors are strongly advised to consult with their tax advisers regarding any potential investment in certain transactions — including those involving futures, options, and other derivatives as well as non-investment-grade securities — that give rise to substantial risk and are not suitable for all investors. The material is based on information that we consider reliable, but we do not represent that it is accurate or complete, and it should not be relied on as such. Opinions expressed are our current opinions as of the date appearing on this material only. We endeavour to update on a reasonable basis the information discussed in this material, but regulatory, compliance, or other reasons may prevent us from doing so.

We and our affiliates, officers, directors, and employees, including persons involved in the preparation or issuance of this material, may from time to time have "long" or "short" positions in, act as principal in, and buy or sell the securities or derivatives thereof of companies mentioned herein and may from time to time add to or dispose of any such securities (or investment). We and our affiliates may assume an underwriting commitment in the securities of companies discussed in this document (or in related investments), may sell them to or buy them from customers on a principal basis, and may also perform or seek to perform investment banking or advisory services for or relating to these companies and may also be represented in the supervisory board or any other committee of these companies.

For the purpose of calculating whether BOBCAPS and its affiliates hold, beneficially own, or control, including the right to vote for directors, one per cent or more of the equity shares of the subject company, the holdings of the issuer of the research report is also included.

BOBCAPS and its non-US affiliates may, to the extent permissible under applicable laws, have acted on or used this research to the extent that it relates to non-US issuers, prior to or immediately following its publication. Foreign currency denominated securities are subject to fluctuations in exchange rates that could have an adverse effect on the value or price of or income derived from the investment. In addition, investors in securities such as ADRs, the value of which are influenced by foreign currencies, effectively assume currency risk. In addition, options involve risks and are not suitable for all investors. Please ensure that you have read and understood the Risk disclosure document before entering into any derivative transactions.

No part of this material may be (1) copied, photocopied, or duplicated in any form by any means or (2) redistributed without BOBCAPS's prior written consent.

#### **Company-specific disclosures under SEBI (Research Analysts) Regulations, 2014**

The research analyst(s) or his/her relatives do not have any material conflict of interest at the time of publication of this research report.

BOBCAPS or its research analyst(s) or his/her relatives do not have any financial interest in the subject company. BOBCAPS or its research analyst(s) or his/her relatives do not have actual/beneficial ownership of one per cent or more securities in the subject company at the end of the month immediately preceding the date of publication of this report.

The research analyst(s) has not received any compensation from the subject company or third party in the past 12 months in connection with research report/activities. Compensation of the research analyst(s) is not based on any specific merchant banking, investment banking or brokerage service transactions.

BOBCAPS or its research analyst(s) is not engaged in any market making activities for the subject company.

The research analyst(s) has not served as an officer, director or employee of the subject company.

BOBCAPS or its associates may have material conflict of interest at the time of publication of this research report.

BOBCAPS's associates may have financial interest in the subject company. BOBCAPS's associates may hold actual / beneficial ownership of one per cent or more securities in the subject company at the end of the month immediately preceding the date of publication of this report.

BOBCAPS or its associates may have managed or co-managed a public offering of securities for the subject company or may have been mandated by the subject company for any other assignment in the past 12 months.

BOBCAPS may have received compensation from the subject company in the past 12 months. BOBCAPS may from time to time solicit or perform investment banking services for the subject company. BOBCAPS or its associates may have received compensation from the subject company in the past 12 months for services in respect of managing or co-managing public offerings, corporate finance, investment banking or merchant banking, brokerage services or other advisory services in a merger or specific transaction. BOBCAPS or its associates may have received compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company in the past 12 months.

#### **Other disclaimers**

BOBCAPS and MAYBANK (as defined below) make no representation or warranty, express or implied, as to the accuracy or completeness of any information obtained from third parties and expressly disclaim the merchantability, suitability, quality and fitness of this report. The information in this report has not been independently verified, is provided on an "as is" basis, should not be relied on by you in connection with any contract or commitment, and should not be used as a substitute for enquiries, procedures and advice which ought to be undertaken by you. This report also does not constitute an offer or solicitation to buy or sell any securities referred to herein and you should not construe this report as investment advice. All opinions and estimates contained in this report constitute BOBCAPS's judgment as of the date of this report and are subject to change without notice, and there is no obligation on BOBCAPS or MAYBANK to update this report upon issuance. This report and the information contained herein may not be reproduced, redistributed, disseminated or copied by any means without the prior consent of BOBCAPS and MAYBANK.

To the full extent permitted by law neither BOBCAPS, MAYBANK nor any of their respective affiliates, nor any other person, accepts any liability howsoever arising, whether in contract, tort, negligence, strict liability or any other basis, including without limitation, direct or indirect, special, incidental, consequential or punitive damages arising from any use of this report or the information contained herein. By accepting this report, you agree and undertake to fully indemnify and hold harmless BOBCAPS and MAYBANK from and against claims, charges, actions, proceedings, losses, liabilities, damages, expenses and demands (collectively, the "Losses") which BOBCAPS and/or MAYBANK may incur or suffer in any jurisdiction including but not limited to those Losses incurred by BOBCAPS and/or MAYBANK as a result of any proceedings or actions brought against them by any regulators and/or authorities, and which in any case are directly or indirectly occasioned by or result from or are attributable to anything done or omitted in relation to or arising from or in connection with this report.

#### **Distribution into the United Kingdom ("UK"):**

This research report will only be distributed in the United Kingdom, in accordance with the applicable laws and regulations of the UK, by Maybank Securities (London) Ltd ("MSL") who is authorised and regulated by the Financial Conduct Authority ("FCA") in the United Kingdom (MSL and its affiliates are collectively referred to as "MAYBANK"). BOBCAPS is not authorized to directly distribute this research report in the UK.

This report has not been prepared by BOBCAPS in accordance with the UK's legal and regulatory requirements.

This research report is for distribution only to, and is solely directed at, selected persons on the basis that those persons: (a) are eligible counterparties and professional clients of MAYBANK as selected by MAYBANK solely at its discretion; (b) have professional experience in matters relating to investments falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended from time to time (the "Order"), or (c) fall within Article 49(2)(a) to (d) (high net worth companies, unincorporated associations, etc. as mentioned in the stated Article) of the Order; (all such persons together being referred to as "relevant persons").

This research report is directed only at relevant persons and must not be acted on or relied on by any persons who are not relevant persons. Any investment or investment activity to which this material relates is available only to relevant persons and will be engaged in only with relevant persons.

The relevant person as recipient of this research report is not permitted to reproduce, change, remove, pass on, distribute or disseminate the data or make it available to third parties without the written permission of BOBCAPS or MAYBANK. Any decision taken by the relevant person(s) pursuant to the research report shall be solely at their costs and consequences and BOBCAPS and MAYBANK shall not have any liability of whatsoever nature in this regard.

#### **No distribution into the US:**

This report will not be distributed in the US and no US person may rely on this communication.

#### **Other jurisdictions:**

This report has been prepared in accordance with SEBI (Research Analysts) Regulations and not in accordance with local regulatory requirements of any other jurisdiction. In any other jurisdictions, this report is only for distribution (subject to applicable legal or regulatory restrictions) to professional, institutional or sophisticated investors as defined in the laws and regulations of such jurisdictions by Maybank Securities Pte Ltd. (Singapore) and / or by any broker-dealer affiliate or such other affiliate as determined by Malayan Banking Berhad.

If the recipient of this report is not as specified above, then it should not act upon this report and return the same to the sender.

By accepting this report, you agree to be bound by the foregoing limitations.